Treatment with an experimental drug in patients with newly diagnosed ALL

What we are studying

This study is trying to determine what affects (good and bad) treatment with blinatumomab has on BCR/ABL negative ALL

Who we are studying

  • Men and Women
  • Races:
    • White
    • African American
    • Asian
    • American Indian or Alaska Native
    • Native Hawaiian or Pacific Islander
    • Other
  • All Ethnicities
  • Ages 35 - 70

Eligibility Criteria

  • Subjects must be between 35-70 years of age

What is involved

  • Study treatment may last up to 3 years

Compensation

None

Contact Information

Study Coordinator
Teresa Brady
Email
tbrady@wakehealth.edu
Phone
336-716-4703

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.